[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575594":3},{"organization":4,"armGroups":7,"interventions":45,"overallOfficials":62,"centralContacts":51,"locations":66,"responsibleParty":80,"collaborators":51,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":51,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":51,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":103,"whyStopped":51,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8,15,19,23,27,31,34,37,41],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Group 1","EXPERIMENTAL","Participants will receive ABBV-142 Dose A or Placebo on Day 1.",[13,14],"Drug: ABBV-142","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 1: Group 2","Participants will receive ABBV-142 Dose B or Placebo on Day 1.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Part 1: Group 3","Participants will receive ABBV-142 Dose C or Placebo on Day 1.",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Part 1: Group 4","Participants will receive ABBV-142 Dose D or Placebo on Day 1.",[13,14],{"label":28,"type":10,"description":29,"interventionNames":30},"Part 1: Group 5 (Optional)","Participants will receive ABBV-142 Dose TBD or Placebo on Day 1.",[13,14],{"label":32,"type":10,"description":17,"interventionNames":33},"Part 2: Group 6",[13,14],{"label":35,"type":10,"description":21,"interventionNames":36},"Part 2: Group 7",[13,14],{"label":38,"type":10,"description":39,"interventionNames":40},"Part 3: Group 8","Han Chinese participants will receive ABBV-142, dose to be determined, or Placebo on Day 1.",[13,14],{"label":42,"type":10,"description":43,"interventionNames":44},"Part 3: Group 9","Japanese participants will receive ABBV-142, dose to be determined, or Placebo on Day 1.",[13,14],[46,52,55,59],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"DRUG","ABBV-142","Intravenous (IV) Infusion",[9,16,20,24,28,38,42],null,{"type":47,"name":48,"description":53,"armGroupLabels":54,"otherNames":51},"Subcutaneous (SC) Injection",[32,35],{"type":47,"name":56,"description":57,"armGroupLabels":58,"otherNames":51},"Placebo","IV Infusion",[9,16,20,24,28,38,42],{"type":47,"name":56,"description":60,"armGroupLabels":61,"otherNames":51},"SC Injection",[32,35],[63],{"name":64,"affiliation":5,"role":65},"ABBVIE INC.","STUDY_DIRECTOR",[67],{"facility":68,"status":51,"city":69,"state":70,"zip":71,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":79,"contacts":51},"Acpru \u002FId# 271899","Grayslake","Illinois","60030","United States","US",{"type":75,"coordinates":76},"Point",[77,78],-88.04175,42.34447,{"lat":78,"lon":77},{"type":81,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR","100575594","phase-1-a-study-to-assess-the-adverse-events-and-how-subcutaneous-sc-injections-and-intravenous-iv-infusions-of-abbv-142-move-through-the-body-of-healthy-adult-participants-100575594",false,"NCT06774313","A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants","A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-142 in Healthy Adult Subjects and Single Doses of ABBV-142 in Healthy Adult Asian Subjects","Inclusion Criteria:\n\nAll Parts:\n\n• Volunteers in general good health.\n\nPart 3, ONLY:\n\nHAN CHINESE Participants:\n\n* Participant must be first- or second-generation Han Chinese of full Chinese parentage (both parents of Han Chinese descent), residing outside of China. Participants must be in general good health.\n* First-generation participants will have been born in China to two parents and four grandparents, who were also born in China, and are of full Chinese descent.\n* Second-generation participants born outside of China must have two parents and four grandparents born in China and are of full Chinese descent.\n\nOR\n\nJAPANESE Participants:\n\n* Participant must be first- or second-generation Japanese parentage (both parents of Japanese descent), residing outside of Japan. Participants must be in general good health.\n* First-generation participants will have been born in Japan to two parents and four grandparents born in Japan and are of full Japanese descent.\n* Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan and are of full Japanese descent.\n\nExclusion Criteria:\n\n* History of any clinically significant illness\u002Finfection\u002Fmajor febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.\n* Use of tobacco or nicotine-containing products within 180 days prior to the first dose of study drug.\n* History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.",true,"ALL","18 Years","55 Years",{"count":94,"type":95},73,"ACTUAL","INTERVENTIONAL",[98],"PHASE1","This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.",[101],"Healthy Volunteer",[101,48],"COMPLETED","2026-05-04",{"date":106,"type":95},"2026-05-06",{"date":108,"type":95},"2025-01-22",{"date":110,"type":95},"2026-04-08",{"name":5,"class":6},1]